Delivery Order SPE2DB22D2009-SPE2DB25FM0PH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $56,453.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on October 14, 2025, with completion targeted for October 15, 2025. This non-competitive, firm fixed-price delivery order represents a procurement of the specialty pharmaceutical product to support federal medical supply needs. The award was issued under a child contract mechanism, leveraging AmerisourceBergen's established relationship with DLA as a...
- The Defense Logistics Agency awarded a delivery order valued at $58,639.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025. This firm fixed price contract, with an ultimate completion date of August 12, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded...
- The Defense Logistics Agency (DLA) awarded a $20,272.36 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. No set-aside designation was applied...
- The Defense Logistics Agency has awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens. The award, issued on July 30, 2025, represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,298.32 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml) on June 27, 2025, with an ultimate completion date of June 30, 2025. This competitive award (no set-aside used) carries firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,709.46 on August 12, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $82,931.17 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 23, 2025, with completion scheduled for September 24, 2025. This competitively awarded, firm fixed-price delivery order represents a single-unit pharmaceutical supply transaction under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $53,153.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 14, 2025, with completion targeted for July 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively procured...
- The Defense Logistics Agency awarded a delivery order valued at $31,746.06 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 12, 2025, with a completion date of September 15, 2025. This firm fixed-price delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The contract does not utilize a...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM0PHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $57,542.31 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA, leveraging the company's position as a critical healthcare solutions provider. The award is structured as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be executed from the company's corporate office in Conshohocken, Pennsylvania. This delivery order exemplifies DLA's ongoing reliance on AmerisourceBergen for specialized pharmaceutical procurement to support military and federal healthcare systems. Dupixent, a biologic medication used primarily for atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe asthma, represents the type of brand-name therapeutic medication supplied under AmerisourceBergen's comprehensive pharmaceutical prime vendor arrangement. The delivery order is part of DLA's broader strategy to maintain a flexible and responsive medical supply chain capable of fulfilling diverse pharmaceutical requirements across Defense Health Agency operations and other federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $57.5k | 7/29/25 |